News & Updates
Filter by Specialty:
Finerenone confers cardiorenal benefits in Chinese CKD, T2D patients
In the subgroup analysis of the phase III FIGARO-DKD trial, the selective nonsteroidal mineralocorticoid receptor antagonist finerenone conferred cardiorenal benefits in Chinese patients with chronic kidney disease (CKD) and type 2 diabetes (T2D). The findings were consistent with that observed in the overall cohort.
Finerenone confers cardiorenal benefits in Chinese CKD, T2D patients
16 Oct 2023
Shorter height, smaller hips linked to higher T2D risk
Most adiposity markers are positively associated with incident type 2 diabetes (T2D), but waist to height ratio (WHtR) shows the most robust association and is a better predictor of T2D risk.
Shorter height, smaller hips linked to higher T2D risk
15 Oct 2023
Physical activity in the morning more effective in preventing obesity than at night
Moderate-to-vigorous physical activity (MVPA) in the morning appears to be more protective against obesity, particularly for individuals who are sedentary for most of the day, a study has found.
Physical activity in the morning more effective in preventing obesity than at night
14 Oct 2023
Understanding the effects of LDL-C lowering on several diseases
Genetic evidence confirms both the positive and negative associations of low-density lipoprotein cholesterol (LDL-C) reduction with certain metabolic and cardiovascular diseases (CVDs), according to the results of a Mendelian randomization (MR) study in the UK Biobank.
Understanding the effects of LDL-C lowering on several diseases
13 Oct 2023
Resistance exercise prevents ADT-induced muscle loss in patients with prostate cancer
Resistance exercise training counters the negative effects of androgen deprivation therapy (ADT) and improves muscle fibre size, as well as capillarization, in patients with prostate cancer, reports a study.
Resistance exercise prevents ADT-induced muscle loss in patients with prostate cancer
09 Oct 2023
Liraglutide vs semaglutide: Which is a better GLP-1 RA for diabetic veterans?
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) liraglutide and semaglutide are both effective at lowering haemoglobin A1c (A1c) among veterans with type 2 diabetes mellitus (T2DM), reports a recent study, which provides insights into key considerations for this population.
Liraglutide vs semaglutide: Which is a better GLP-1 RA for diabetic veterans?
06 Oct 2023
Early use of DPP-4 inhibitors delays insulin initiation in Chinese T2D patients
Early dipeptidyl peptidase 4 (DPP-4) inhibitor intensification delays insulin initiation in Chinese patients with type 2 diabetes (T2D), a cohort study in Hong Kong has shown.
Early use of DPP-4 inhibitors delays insulin initiation in Chinese T2D patients
06 Oct 2023
Icodec with app superior to OD analogues in insulin-naive T2D
Once-weekly insulin icodec with a dosing guide app is better than once-daily (OD) basal insulin analogues at reducing glycated haemoglobin (HbA1c) and improving treatment satisfaction and compliance in patients with type 2 diabetes (T2D), a study has shown. In addition, hypoglycaemia rates were low and similar between treatment groups.